Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Name: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Published: 2021
License: Public Domain

Novartis Pharmaceuticals · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

differentiated thyroid cancer (dtc), locally advanced or metastatic differentiated thyroid cancer, radio active iodine refractory, previously targeted therapy, b-raf proto-oncogene, serine/threonine kinase (braf), brafv600e mutation, dabrafenib (drb436), trametinib (tmt212), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Related documents